Access BioTech
Status
ACTIVE
Global HQ
Boston, United States
Countries of investment
- United Kingdom
- USA
Investment stages
- Seed
- Series A
Industries
- Fintech
- Logistics
About
Access BioTech, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to late stage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.
Access BioTech, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to late stage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.
Investment Thesis
Access BioTech invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health.
Access BioTech Contacts Information
Secondary contact
Portfolio
Crest Capital
Beech Tree
Novum Capital
Ancala